$ALLO

David Chang Sells 47,763 Shares of Allogene Therapeutics (NASDAQ:ALLO) Stock

Allogene Therapeutics CEO David Chang sold 47,763 shares of the company's stock on March 16th, reducing his stake by 0.92%. The transaction, valued at over $117,000, leaves him with approximately 5.15 million shares. Despite the insider selling, analysts maintain a "Moderate Buy" rating for ALLO with an average price target of $8.50, and the company recently beat EPS estimates.

Original reporting
MarketBeat · MarketBeat
Published Mar 19, 2026, 1:08 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Mar 19, 2026, 1:30 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
David Chang Sells 47,763 Shares of Allogene Therapeutics (NASDAQ:ALLO) Stock — source image
Decision brief

The 30-second read

$ALLONeutralLow
01

Why it matters

While insider sales can sometimes signal caution, in this case, the company's recent earnings beat and maintained analyst ratings suggest limited impact on the stock's fundamentals.

02

Market read

The insider sale is a moderate event with limited immediate impact on the stock's outlook, but warrants monitoring for future insider activity.

03

What to watch

Recent earnings beat and analyst ratings suggest the company's prospects remain positive despite insider activity.

Timing: short-term

Background

David Chang, CEO of Allogene Therapeutics, sold 47,763 shares on March 16, reducing his stake by 0.92%. The transaction was valued at over $117,000.

Company-level read

Ticker impact

$ALLONeutralMedium confidence
Context

The insider selling of Allogene Therapeutics shares may indicate a lack of confidence or liquidity considerations by key executives.

Expected impact

Potential short-term slight decline or stabilization; long-term impact uncertain due to conflicting signals.

Evidence & confidence

While insider sales can signal caution, the company's recent earnings beat and maintained analyst ratings suggest limited immediate downside. The sale constitutes approximately 0.92% of holdings, which is moderate.

Market effects

The biotech sector may experience minor negative sentiment due to insider sales in a key player.

Limited; primarily affects investor perception of ALLO.

negligible; specific to ALLO and biotech sector.

Counterpoint

Insider selling may be for personal liquidity needs and not indicative of company fundamentals.

Key entities

  • David Chang

    CEO of Allogene Therapeutics.

  • Allogene Therapeutics

    Biotech company focused on cell therapies.

Related articles

$BKRMed

Baker Hughes extends long-term service deal for Nigeria LNG Train 7

Baker Hughes said it won a 13-year lifecycle services deal with Nigeria LNG for turbomachinery at NLNG’s Train 7 expansion on Bonny Island. The scope covers heavy-duty gas turbines, centrifugal compressors, remote monitoring via Baker Hughes’ digital platform, and local support. Train 7 is expected to raise capacity from 22 to 30 MMtpa.

$BKRMed

Baker Hughes wins subsea systems contract for Angola's Greater PAJ field

Baker Hughes said it won a contract from Azule Energy to supply subsea production systems for the Greater PAJ ultra-deepwater project offshore Angola. Scope includes horizontal subsea trees, control modules, workover control systems and related equipment plus installation and support. Greater PAJ is expected to start producing in 2029 via an FPSO processing up to 95,000 bpd, with deliveries starting in 2027.

$WENMed

57-year-old Burger chain closed 28 restaurants, 100s more coming

Wendy’s (WEN) said it closed 28 restaurants and expects to close 5% to 6% of U.S. units (about 289 to 358) in 1H 2026, with possible additional selective closures. The company reported 2Q FY2026 systemwide sales down 6.5% YoY, U.S. systemwide down 8.2%, and U.S. same-restaurant sales down 7%. Wendy’s launched a turnaround plan and withdrew its 2026 outlook.

$ACIMed

Albertsons recalls ready-to-eat items in multiple states amid salmonella-linked jalapeño investigation

Albertsons Companies said it is voluntarily recalling four ready-to-eat products containing jalapeños supplied by Taylor Farms, including items sold at Randalls in Texas. The recall followed a supplier recall tied to an ongoing federal investigation and an FDA probe of a Salmonella Javiana outbreak. FDA reported 345 illnesses in 27 states, 36 hospitalizations, no deaths.

$CMGMed

Salmonella outbreak from Mexican jalapeños reported in 27 U.S. states

U.S. health authorities are investigating a Salmonella outbreak linked to Mexican jalapeño peppers. The CDC and FDA say 345 people are ill across 27 states, with 36 hospitalizations and no deaths. The supplier, Coast Citrus Distributors, recalled peppers sent to restaurants including Chipotle and QDOBA. Chipotle removed jalapeños from some outlets and shares fell over 8% on Aug. 4.